Group Leader/s
Head of lab
intro
Our research group seeks to delve into the cellular and molecular bases of pulmonary vascular dysfunction, the gateway to the body for a multitude of agents capable of compromising people's health. Our research places a special focus on understanding endothelial damage and its connection with vascular smooth muscle and the immune system, all of which are very present in the development of cardiovascular diseases. We go from rare or infrequent diseases such as pulmonary arterial hypertension to other cardiopulmonary disorders resulting from exposure to various environmental factors, such as hypoxia, certain pollutants, drugs or respiratory infections. All these cardiopulmonary diseases affect both the lung vasculature and the heart in one way or another. The ultimate goal of our research is to find new targets, biomarkers and therapeutic strategies that contribute, from basic biology and experimental pharmacology, to solving the health challenges of our society.
Selected Publications
*Clemente-Moragón, A., *Martínez-Milla, J., Oliver, E., Santos, A., Flandes, J., Fernández, I., Rodríguez-González, L., Serrano Del Castillo, C., Ioan, A. M., López-Álvarez, M., Gómez-Talavera, S., Galán-Arriola, C., Fuster, V., Pérez-Calvo, C., & Ibáñez, B. (*equally contributed) [2021]. Metoprolol in Critically Ill Patients With COVID-19. Journal of the American College of Cardiology, 78(10), 1001–1011.
Galán-Arriola, C., Vílchez-Tschischke, J. P., Lobo, M., López, G. J., de Molina-Iracheta, A., Pérez-Martínez, C., Villena-Gutiérrez, R., Macías, Á., Díaz-Rengifo, I. A., Oliver, E., Fuster, V., Sánchez-González, J., & Ibanez, B. [2022]. Coronary microcirculation damage in anthracycline cardiotoxicity. Cardiovascular research, 118(2), 531–541.
Galán-Arriola, C., Villena-Gutiérrez, R., Higuero-Verdejo, M. I., Díaz-Rengifo, I. A., Pizarro, G., López, G. J., Molina-Iracheta, A., Pérez-Martínez, C., García, R. D., González-Calle, D., Lobo, M., Sánchez, P. L., Oliver, E., Córdoba, R., Fuster, V., Sánchez-González, J., & Ibanez, B. [2021]. Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovascular research, 117(4), 1132–1143.
Clemente-Moragón, A., Gómez, M., Villena-Gutiérrez, R., Lalama, D. V., García-Prieto, J., Martínez, F., Sánchez-Cabo, F., Fuster, V., *Oliver, E., & *Ibáñez, B. (*co-corresponding authors) [2020]. Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation. European heart journal, 41(46), 4425–4440.
Spaczyńska, M., Rocha, S. F., & *Oliver, E. (*corresponding author) [2020]. Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies. ACS pharmacology & translational science, 3(4), 598–612.
Nuche, J., Segura de la Cal, T., Jiménez López Guarch, C., López-Medrano, F., Delgado, C. P., Ynsaurriaga, F. A., Delgado, J. F., Ibáñez, B., *Oliver, E., & *Subías, P. E. (*co-corresponding authors). [2020]. Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. Diagnostics (Basel, Switzerland), 10(8), 548.
*Oliver, E., Mayor, F., Jr, & D'Ocon, P. (*corresponding author). [2019]. Beta-blockers: Historical Perspective and Mechanisms of Action. Revista espanola de cardiologia (English ed.), 72(10), 853–862.
Galán-Arriola, C., Lobo, M., Vílchez-Tschischke, J. P., López, G. J., de Molina-Iracheta, A., Pérez-Martínez, C., Agüero, J., Fernández-Jiménez, R., Martín-García, A., Oliver, E., Villena-Gutierrez, R., Pizarro, G., Sánchez, P. L., Fuster, V., Sánchez-González, J., & Ibanez, B. [2019]. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. Journal of the American College of Cardiology, 73(7), 779–791.
*Zhao, L., *Oliver, E., Maratou, K., Atanur, S. S., Dubois, O. D., Cotroneo, E., Chen, C. N., Wang, L., Arce, C., Chabosseau, P. L., Ponsa-Cobas, J., Frid, M. G., Moyon, B., Webster, Z., Aldashev, A., Ferrer, J., Rutter, G. A., Stenmark, K. R., Aitman, T. J., & Wilkins, M. R. (*co-first authors). [2015]. The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. Nature, 524(7565), 356–360.
George, P. M., Oliver, E., Dorfmuller, P., Dubois, O. D., Reed, D. M., Kirkby, N. S., Mohamed, N. A., Perros, F., Antigny, F., Fadel, E., Schreiber, B. E., Holmes, A. M., Southwood, M., Hagan, G., Wort, S. J., Bartlett, N., Morrell, N. W., Coghlan, J. G., Humbert, M., Zhao, L., Mitchell, J. A. [2014]. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circulation research, 114(4), 677–688.
Watson, G., Oliver, E., Zhao, L., & Wilkins, M. R. [2013]. Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers). Handbook of experimental pharmacology, 218, 531–548.
Zhao, L., Chen, C. N., Hajji, N., Oliver, E., Cotroneo, E., Wharton, J., Wang, D., Li, M., McKinsey, T. A., Stenmark, K. R., & Wilkins, M. R. [2012]. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation, 126(4), 455–467.
Wojciak-Stothard, B., Zhao, L., Oliver, E., Dubois, O., Wu, Y., Kardassis, D., Vasilaki, E., Huang, M., Mitchell, J. A., Harrington, L. S., Prendergast, G. C., & Wilkins, M. R. [2012]. Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circulation research, 110(11), 1423–1434.
Oliver, E., Rovira, E., Montó, F., Valldecabres, C., Julve, R., Muedra, V., Ruiz, N., Barettino, D., & D'Ocon, P. [2010]. beta-Adrenoceptor and GRK3 expression in human lymphocytes is related to blood pressure and urinary albumin excretion. Journal of hypertension, 28(6), 1281–1289.
Oliver, E., Martí, D., Montó, F., Flacco, N., Moreno, L., Barettino, D., Ivorra, M. D., & D'Ocon, P. [2009]. The impact of alpha1-adrenoceptors up-regulation accompanied by the impairment of beta-adrenergic vasodilatation in hypertension. The Journal of pharmacology and experimental therapeutics, 328(3), 982–990.
Funding
Funded by Ministerio de Ciencia e Innovación / Agencia Estatal de Investigación (RYC2020-028884-I and PID2021-123167OB-I00) and by CSIC Talent Attraction program (PIE 20222AT010).
More info
Patents
Oliver E, Zhao L, Wilkins MR, and Aitman T. PCT/GB2016/052297. ZIP12 as a Therapeutic/Screening Candidate for Hypoxia-Induced Pulmonary Hypertension WO/2017/017446. Priority: UK (extended to world-wide application), Date: 28/07/2015. Status: entered into national phases in EP and US. Holder: Imperial Innovations Ltd.
Honors and Awards
- Ramón y Cajal Fellow. Agencia Estatal de Investigación. 2022-2017
- ‘Prismas’ Honorific mention to the singular project modality for the initiative #CienciaenelParlamento. Museos Científicos Coruñeses. 2019
- SRUK Mentoring recognition award. SRUK/CERU. 2018
- Talent Atraction Senior Fellow (mod.1). Comunidad Autónoma de Madrid. 2018-2022
- 1st Prize in Biological and Biomedical Sciences for Tutors. 16th ARQUIMEDES University Contest. Ministry of Education, Culture and Sports. 2017
- Winner of the 32nd SEF Young Investigator Award to best career under 35 years old. Spanish Society of Pharmacology (SEF). 2017
- Winner of the EPHAR Young Investigator Award. The Federation of European Pharmacological Societies (EPHAR). 2016
- International Postdoctoral CNIC Fellow. Marie Sklodowska-Curie COFUND. 2016-2018
- Expert on expatriate scientific networks. 'Los 100 de Cotec', Fundacion Cotec. 2016
- FPU Phd Fellow. Ministry of Science and Education. 2005-2009
*We are looking for candidates to do a Master and/or PhD with us! If you are interested in joining our group, send an e-mail to Eduardo including your CV and a motivation letter.